Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.

It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.

The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020.

Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.